Cargando…

Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease

BACKGROUND: Advanced chronic kidney disease (CKD) is a common complication for people with type 1 and 2 diabetes and can often lead to glucose instability. Continuous glucose monitoring (CGM) helps users monitor and stabilize their glucose levels. To date, CGM and intermittent scanning CGM are only...

Descripción completa

Detalles Bibliográficos
Autores principales: Ólafsdóttir, Arndís Finna, Andelin, Mervi, Saeed, Aso, Sofizadeh, Sheyda, Hamoodi, Hussein, Jansson, Per-Anders, Lind, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372866/
https://www.ncbi.nlm.nih.gov/pubmed/36158498
http://dx.doi.org/10.12998/wjcc.v10.i22.7794
_version_ 1784767481667125248
author Ólafsdóttir, Arndís Finna
Andelin, Mervi
Saeed, Aso
Sofizadeh, Sheyda
Hamoodi, Hussein
Jansson, Per-Anders
Lind, Marcus
author_facet Ólafsdóttir, Arndís Finna
Andelin, Mervi
Saeed, Aso
Sofizadeh, Sheyda
Hamoodi, Hussein
Jansson, Per-Anders
Lind, Marcus
author_sort Ólafsdóttir, Arndís Finna
collection PubMed
description BACKGROUND: Advanced chronic kidney disease (CKD) is a common complication for people with type 1 and 2 diabetes and can often lead to glucose instability. Continuous glucose monitoring (CGM) helps users monitor and stabilize their glucose levels. To date, CGM and intermittent scanning CGM are only approved for people with diabetes but not for those with advanced CKD. AIM: To compare the performance of Dexcom G5 and FreeStyle Libre sensors in adults with type 1 or 2 diabetes and advanced CKD. METHODS: This was a non-randomized clinical trial that took place in two outpatient clinics in western Sweden. All patients with type 1 or 2 diabetes and an estimated glomerular filtration rate (eGFR) of < 30 mL/min per 1.73 m(2) were invited to participate. Forty patients (full analysis set = 33) carried the Dexcom G5 sensor for 7 d and FreeStyle Libre sensor for 14 d simultaneously. For referencing capillary blood glucose (SMBG) was measured with a high accuracy glucose meter (HemoCue(®)) during the study period. At the end of the study, all patients were asked to answer a questionnaire on their experience using the sensors. RESULTS: The mean age was 64.1 (range 41-77) years, hemoglobin A1c was 7.0% [standard deviation (SD) 3.2], and diabetes duration was 28.5 (SD 14.7) years. A total of 27.5% of the study population was on hemodialysis and 22.5% on peritoneal dialysis. The mean absolute relative difference for Dexcom G5 vs SMBG was significantly lower than that for FreeStyle Libre vs SMBG [15.2% (SD 12.2) vs 20.9% (SD 8.6)], with a mean difference of 5.72 [95% confidence interval (CI): 2.11-9.32; P = 0.0036]. The mean absolute difference was also significantly lower for Dexcom G5 than for FreeStyle Libre, 1.21 mmol/L (SD 0.78) and 1.76 mmol/L (SD 0.78), with a mean diffrenec of 0.55 (95%CI: 0.27-0.83; P = 0.0004).The mean difference (MD) was -0.107 mmol/L and -1.10 mmol/L (P = 0.0002), respectively. In all, 66% of FreeStyle Libre values were in the no risk zone on the surveillance error grid compared to 82% of Dexcom G5 values. CONCLUSION: Dexcom G5 produces more accurate sensor values than FreeStyle Libre in people with diabetes and advanced CKD and is likely safe to be used by those with advanced CKD.
format Online
Article
Text
id pubmed-9372866
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-93728662022-09-23 Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease Ólafsdóttir, Arndís Finna Andelin, Mervi Saeed, Aso Sofizadeh, Sheyda Hamoodi, Hussein Jansson, Per-Anders Lind, Marcus World J Clin Cases Clinical Trials Study BACKGROUND: Advanced chronic kidney disease (CKD) is a common complication for people with type 1 and 2 diabetes and can often lead to glucose instability. Continuous glucose monitoring (CGM) helps users monitor and stabilize their glucose levels. To date, CGM and intermittent scanning CGM are only approved for people with diabetes but not for those with advanced CKD. AIM: To compare the performance of Dexcom G5 and FreeStyle Libre sensors in adults with type 1 or 2 diabetes and advanced CKD. METHODS: This was a non-randomized clinical trial that took place in two outpatient clinics in western Sweden. All patients with type 1 or 2 diabetes and an estimated glomerular filtration rate (eGFR) of < 30 mL/min per 1.73 m(2) were invited to participate. Forty patients (full analysis set = 33) carried the Dexcom G5 sensor for 7 d and FreeStyle Libre sensor for 14 d simultaneously. For referencing capillary blood glucose (SMBG) was measured with a high accuracy glucose meter (HemoCue(®)) during the study period. At the end of the study, all patients were asked to answer a questionnaire on their experience using the sensors. RESULTS: The mean age was 64.1 (range 41-77) years, hemoglobin A1c was 7.0% [standard deviation (SD) 3.2], and diabetes duration was 28.5 (SD 14.7) years. A total of 27.5% of the study population was on hemodialysis and 22.5% on peritoneal dialysis. The mean absolute relative difference for Dexcom G5 vs SMBG was significantly lower than that for FreeStyle Libre vs SMBG [15.2% (SD 12.2) vs 20.9% (SD 8.6)], with a mean difference of 5.72 [95% confidence interval (CI): 2.11-9.32; P = 0.0036]. The mean absolute difference was also significantly lower for Dexcom G5 than for FreeStyle Libre, 1.21 mmol/L (SD 0.78) and 1.76 mmol/L (SD 0.78), with a mean diffrenec of 0.55 (95%CI: 0.27-0.83; P = 0.0004).The mean difference (MD) was -0.107 mmol/L and -1.10 mmol/L (P = 0.0002), respectively. In all, 66% of FreeStyle Libre values were in the no risk zone on the surveillance error grid compared to 82% of Dexcom G5 values. CONCLUSION: Dexcom G5 produces more accurate sensor values than FreeStyle Libre in people with diabetes and advanced CKD and is likely safe to be used by those with advanced CKD. Baishideng Publishing Group Inc 2022-08-06 2022-08-06 /pmc/articles/PMC9372866/ /pubmed/36158498 http://dx.doi.org/10.12998/wjcc.v10.i22.7794 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Clinical Trials Study
Ólafsdóttir, Arndís Finna
Andelin, Mervi
Saeed, Aso
Sofizadeh, Sheyda
Hamoodi, Hussein
Jansson, Per-Anders
Lind, Marcus
Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
title Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
title_full Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
title_fullStr Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
title_full_unstemmed Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
title_short Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
title_sort performance of dexcom g5 and freestyle libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
topic Clinical Trials Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372866/
https://www.ncbi.nlm.nih.gov/pubmed/36158498
http://dx.doi.org/10.12998/wjcc.v10.i22.7794
work_keys_str_mv AT olafsdottirarndisfinna performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease
AT andelinmervi performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease
AT saeedaso performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease
AT sofizadehsheyda performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease
AT hamoodihussein performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease
AT janssonperanders performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease
AT lindmarcus performanceofdexcomg5andfreestylelibresensorstestedsimultaneouslyinpeoplewithtype1or2diabetesandadvancedchronickidneydisease